3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Non-Hodgkin
4
Lymphoma, Follicular
3
Lymphoma
3
Recurrence
2
Lymphoma, B-Cell
2
Waldenstrom Macroglobulinemia
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia
1
Immunoproliferative Disorders
1
Interventions
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Immunoproliferative Disorders
×
Rituximab
×
Clear all
NCT01277172
2011-01-14
TREND
Probiomed S.A. de C.V.
Phase 2/3
Unknown
54 enrolled